Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 182

Gyromagnetic zero-index metamaterials enable stable light vortices for advanced optical control

The Hong Kong University of Science and Technology (HKUST)-led research team has adopted gyromagnetic double-zero-index metamaterials (GDZIMs)—a new optical extreme-parameter material—and developed a new method to control light using GDZIMs. This discovery could revolutionize fields like optical communications, biomedical imaging, and nanotechnology, enabling advances in integrated photonic chips, high-fidelity optical communication, and quantum light sources.

The study published in Nature was co-led by Prof. Chan Che-Ting, Interim Director of the HKUST Jockey Club Institute for Advanced Study and Chair Professor in the Department of Physics, and Dr. Zhang Ruoyang, Visiting Scholar in the Department of Physics at HKUST.

Cellular coordinate system reveals secrets of active matter

All humans who have ever lived were once each an individual cell, which then divided countless times to produce a body made up of about 10 trillion cells. These cells have busy lives, executing all kinds of dynamic movement: contracting every time we flex a muscle, migrating toward the site of an injury, and rhythmically beating for decades on end.

Cells are an example of active matter. As inanimate matter must burn fuel to move, like airplanes and cars, active matter is similarly animated by its consumption of energy. The basic molecule of cellular energy is (ATP), which catalyzes that enable cellular machinery to work.

Caltech researchers have now developed a bioengineered coordinate system to observe the movement of cellular machinery. The research enables a better understanding of how cells create order out of chaos, such as during or in the organized movements of chromosomes that are a prerequisite to faithful cell division.

New proposal aims to protect patients with high-risk brain implants

As companies such as Elon Musk’s Neuralink begin human trials of high-risk brain implants, a new proposal calls for a major change in how the U.S. handles injuries caused by the devices.

The article published in Science suggests a “no-fault” compensation program to help harmed by devices like (BCIs)—even when no one is legally at fault.

These devices, which are implanted in the brain to treat serious conditions like epilepsy or paralysis, can offer life-changing benefits. But they also come with serious risks such as seizures, strokes or even death. And when something goes wrong, patients often have no way to get help or compensation.

Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions

In recent years, ADCs have emerged as a transformative therapeutic modality in oncology, offering a promising avenue for the treatment of bladder cancer. ADCs combine the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic agents, enabling targeted delivery of payloads to tumor cells while sparing healthy tissues. This unique mechanism of action has led to significant advancements in the treatment landscape, particularly for cancers that are resistant to conventional therapies (5). In bladder cancer, ADCs have demonstrated remarkable efficacy by targeting specific tumor-associated antigens, such as nectin-4 and HER2, thereby inducing tumor cell apoptosis and inhibiting metastasis. For example, Enfortumab vedotin (targeting NECTIN-4) achieved a median overall survival of 12.9 months in the EV-301 trial (vs. 9.0 months with chemotherapy) (6). Similarly, trastuzumab deruxtecan, a HER2-directed ADC, has demonstrated promising antitumor activity in HER2-expressing bladder cancer (7), offering a potential therapeutic option for this subset of patients.

Despite these promising developments, several challenges persist in the clinical application of ADCs for bladder cancer. Key issues include the durability of therapeutic responses, the management of off-target toxicities, and the heterogeneity of antigen expression across different patient subtypes (8). Moreover, the optimal integration of ADCs with existing treatment paradigms, such as immune checkpoint inhibitors and chemotherapy, remains an area of active investigation (9). Addressing these challenges is crucial for maximizing the therapeutic potential of ADCs and improving patient outcomes.

This study provides a comprehensive evaluation of the current landscape of ADC-based therapies for bladder cancer, with a focus on their mechanisms of action, clinical efficacy, and safety profiles. We systematically review ongoing clinical trials, highlighting the most promising ADC candidates and their respective targets. Furthermore, we explore emerging strategies to enhance the precision and durability of ADC therapies, including the development of novel linkers, payloads, and antibody engineering techniques. By synthesizing the latest clinical data, this review aims to offer valuable insights into the future directions of ADC research and their potential to revolutionize bladder cancer treatment. Our findings underscore the importance of continued innovation in ADC technology and the need for personalized approaches to overcome the limitations of current therapies, ultimately paving the way for more effective and safer treatment options for patients with bladder cancer.

Training robots without robots: Smart glasses capture first-person task demos

Over the past few decades, robots have gradually started making their way into various real-world settings, including some malls, airports and hospitals, as well as a few offices and households.

For robots to be deployed on a larger scale, serving as reliable everyday assistants, they should be able to complete a wide range of common manual tasks and chores, such as cleaning, washing the dishes, cooking and doing the laundry.

Training machine learning algorithms that allow robots to successfully complete these tasks can be challenging, as it often requires extensive annotated data and/or demonstration videos showing humans the tasks. Devising more effective methods to collect data to train robotics algorithms could thus be highly advantageous, as it could help to further broaden the capabilities of robots.

This 70-year-old doctor is stronger than ever, and here is HOW he achieved his fitness (no, not just through cardio)

Dr. Eric Topol, a 70-year-old cardiologist, challenges conventional aging perceptions by embracing strength training. Abandoning cardio, he discovered that building muscle mass significantly improves health span. His regimen of simple exercises at home led to increased strength, balance, mental focus, and confidence, proving that aging can be a period of renewal, not decline.

Cancer cells use cholesterol armor to survive heat shock treatment, study discovers

Since the time of the ancient Greek physician Hippocrates, cancer has been recognized as being sensitive to heat. Today, this principle forms the basis of hyperthermia treatment—a promising cancer therapy that uses controlled heat to kill tumor cells while sparing healthy ones.

Unlike chemotherapy or radiation, hyperthermia works by heating cancerous tissue to temperatures around 50°C, causing cancer while simultaneously activating the body’s immune system against the tumor. This approach holds particular promise when combined with immunotherapy, as heat-killed cancer cells can trigger a stronger anti-tumor immune response.

However, a few major challenges have limited hyperthermia’s clinical success. One of the main hurdles is the limited understanding of the biological mechanisms behind heat sensitivity in cancer cells. Researchers have discovered that some cancer cells—even those from the same organ—react differently to heat shock, with some surprisingly more heat-resistant than others.

Scientists design a new tumor-targeting system for cancer fighting cells

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors. While similar treatments have worked well for blood cancers, treating solid tumors is more difficult. Their method targeted a protein found in high amounts on many types of cancer cells (Eva1) and successfully eliminated tumors in lab mice.

A protein that appears on malignant tumors may hold the key to successful treatment.

/* */